Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for biliary tract tumor after failure of gemcitabine plus platinum
ChiCTR1800018332Phase 2Recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in biliary cancer and cholangiocarcinoma (CCA), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Progression-free survival. Started Aug 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
biliary cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR1800018332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018332.